[{"id":"2fd38c52-b64b-4e26-aac4-6e079d9c3e0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05991947","created_at":"2023-08-15T19:10:06.072Z","updated_at":"2024-07-02T16:35:39.996Z","phase":"","brief_title":"Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer","source_id_and_acronym":"NCT05991947","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • HRAS • CDKN2A • AKT1 • TOP2A • IL6 • RNF43 • CTNNB1 • FBXW7 • MUC16 • GNAS • PPP2R1A","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • FGFR2 mutation • RNF43 mutation • AKT1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • HRAS • CDKN2A • AKT1 • TOP2A • IL6 • RNF43 • CTNNB1 • FBXW7 • MUC16 • GNAS • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • FGFR2 mutation • RNF43 mutation • AKT1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1100","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-08-15"},{"id":"b7c03e6b-1663-4811-9fae-647591bf7c17","acronym":"","url":"https://clinicaltrials.gov/study/NCT00493870","created_at":"2021-01-18T01:45:59.985Z","updated_at":"2024-07-02T16:35:54.351Z","phase":"Phase 3","brief_title":"TAC Versus TC for Adjuvant Breast Cancer","source_id_and_acronym":"NCT00493870","lead_sponsor":"US Oncology Research","biomarkers":" HER-2 • ER • PGR • TOP2A","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR negative","tags":["HER-2 • ER • PGR • TOP2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 1961","initiation":"Initiation: 05/29/2007","start_date":" 05/29/2007","primary_txt":" Primary completion: 05/31/2015","primary_completion_date":" 05/31/2015","study_txt":" Completion: 03/30/2020","study_completion_date":" 03/30/2020","last_update_posted":"2023-03-02"},{"id":"ef0c1229-da88-40d1-bd33-d234575f99ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT00887536","created_at":"2021-01-18T03:23:46.974Z","updated_at":"2024-07-02T16:36:11.859Z","phase":"Phase 3","brief_title":"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer","source_id_and_acronym":"NCT00887536","lead_sponsor":"NSABP Foundation Inc","biomarkers":" HER-2 • ER • PGR • TOP2A","pipe":" | ","alterations":" ER positive • HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR • TOP2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • docetaxel • doxorubicin hydrochloride • cyclophosphamide • Neulasta (pegfilgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 1613","initiation":"Initiation: 05/01/2009","start_date":" 05/01/2009","primary_txt":" Primary completion: 02/01/2018","primary_completion_date":" 02/01/2018","study_txt":" Completion: 02/01/2018","study_completion_date":" 02/01/2018","last_update_posted":"2022-04-20"},{"id":"af8d0c23-6dbe-45dd-97c4-2512fee75af7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04401670","created_at":"2021-01-18T21:14:04.751Z","updated_at":"2024-07-02T16:36:44.805Z","phase":"","brief_title":"Cervical Cancer Screening in Cameroon","source_id_and_acronym":"NCT04401670","lead_sponsor":"Albert Einstein College of Medicine","biomarkers":" CDKN2A • TOP2A","pipe":"","alterations":" ","tags":["CDKN2A • TOP2A"],"overall_status":"Completed","enrollment":" Enrollment 873","initiation":"Initiation: 04/25/2017","start_date":" 04/25/2017","primary_txt":" Primary completion: 08/01/2019","primary_completion_date":" 08/01/2019","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2020-05-25"},{"id":"056223f5-9b84-49c2-a56b-ddafa97c5548","acronym":"","url":"https://clinicaltrials.gov/study/NCT00898898","created_at":"2021-01-18T03:27:15.701Z","updated_at":"2024-07-02T16:36:58.448Z","phase":"","brief_title":"Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831","source_id_and_acronym":"NCT00898898","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" HER-2 • MYC • PTEN • TOP2A","pipe":" | ","alterations":" HER-2 positive • MYC expression • TOP2A amplification","tags":["HER-2 • MYC • PTEN • TOP2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MYC expression • TOP2A amplification"],"overall_status":"Completed","enrollment":" Enrollment 2837","initiation":"Initiation: 05/01/2000","start_date":" 05/01/2000","primary_txt":" Primary completion: 01/01/2010","primary_completion_date":" 01/01/2010","study_txt":" Completion: 04/01/2019","study_completion_date":" 04/01/2019","last_update_posted":"2019-07-02"},{"id":"754bd7c0-262b-42ae-873c-8545c929aa1f","acronym":"READ","url":"https://clinicaltrials.gov/study/NCT00689156","created_at":"2021-01-18T02:34:35.273Z","updated_at":"2024-07-02T16:37:11.731Z","phase":"Phase 3","brief_title":"Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer","source_id_and_acronym":"NCT00689156 - READ","lead_sponsor":"Danish Breast Cancer Cooperative Group","biomarkers":" HER-2 • PGR • TOP2A","pipe":" | ","alterations":" HER-2 positive • HR positive • HR negative • PGR negative","tags":["HER-2 • PGR • TOP2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HR negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cyclophosphamide • epirubicin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 2015","initiation":"Initiation: 06/01/2008","start_date":" 06/01/2008","primary_txt":" Primary completion: 01/01/2013","primary_completion_date":" 01/01/2013","study_txt":" Completion: 01/01/2013","study_completion_date":" 01/01/2013","last_update_posted":"2018-04-05"},{"id":"f412d8b7-c38d-4dfc-bd9c-450eede35f40","acronym":"","url":"https://clinicaltrials.gov/study/NCT00493649","created_at":"2021-01-18T01:45:57.099Z","updated_at":"2024-07-02T16:37:27.781Z","phase":"Phase 2","brief_title":"Adj TC + Herceptin Early Stage Breast Cancer","source_id_and_acronym":"NCT00493649","lead_sponsor":"US Oncology Research","biomarkers":" HER-2 • TOP2A","pipe":" | ","alterations":" TOP2A amplification","tags":["HER-2 • TOP2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TOP2A amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • cyclophosphamide • AP06 (trastuzumab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 493","initiation":"Initiation: 06/01/2007","start_date":" 06/01/2007","primary_txt":" Primary completion: 04/01/2013","primary_completion_date":" 04/01/2013","study_txt":" Completion: 04/01/2013","study_completion_date":" 04/01/2013","last_update_posted":"2016-11-03"}]